Iza-bren and Tagrisso combination showed a 100% objective response rate in EGFR-mutant NSCLC at a 2.5 mg/kg dose. The 12-month progression-free survival and overall survival rates were 92% and 95%, ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of ...
Longer-term follow up in the FLAURA2 Phase III trial confirms the favorable benefit-risk profile of this combination Overall survival results reinforce TAGRISSO as the backbone therapy in EGFRm lung ...
Around 30,000 people annually in the U.S. with non-small cell lung cancer (NSCLC) also get diagnosed with specific epidermal growth factor receptor (EGFR) gene mutations, a condition that affects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results